Form 4: Catalyst Pharma Chairman McEnany Acquires Shares

Patrick J. McEnany, Chairman of Catalyst Pharmaceuticals, acquired 3,534 shares of common stock through the vesting of restricted stock units.

Summary

• Patrick J. McEnany, a Director and Chairman of the Board of Catalyst Pharmaceuticals, Inc. (CPRX), acquired 3,534 shares of common stock.
• The acquisition occurred on December 8, 2025, as a result of the vesting of restricted stock units (RSUs).
• Each restricted stock unit represents a contingent right to receive one share of the company's common stock upon vesting.
• Following this transaction, McEnany beneficially owns 4,152,011 shares of common stock directly.
• He also beneficially owns 1,878,282 restricted stock units directly.
• The RSUs vested in three equal tranches: 1/3rd on December 8, 2024, 1/3rd on December 8, 2025, and 1/3rd on December 8, 2026.
• The 3,534 shares delivered correspond to the second tranche that vested on December 8, 2025.

Sentiment

Score: 7

Explanation: The acquisition of shares by the Chairman through RSU vesting is a positive signal of alignment with shareholder interests and confidence in the company, though it's a routine compensation event rather than a discretionary open-market purchase.

Positives

• Increased direct ownership by a key executive (Chairman of the Board) signals confidence in the company's future.
• The vesting of restricted stock units is a standard compensation mechanism, aligning management's interests with shareholders.

Stakeholder Impact

• Shareholders may view the increased direct ownership by the Chairman as a positive indicator of management's commitment and belief in the company's long-term prospects.

Next Steps

• The final tranche of restricted stock units is scheduled to vest on December 8, 2026, at which point additional shares of common stock will be delivered to the reporting person.

Key Dates

Recommendation

This Form 4 filing details a routine vesting of restricted stock units for the Chairman, leading to an increase in his direct share ownership. While insider ownership is generally positive, this is a scheduled compensation event rather than a discretionary open-market purchase, and thus does not provide new fundamental information to warrant a change in investment recommendation. The transaction aligns management's interests with shareholders but does not signal a new strategic direction or significant financial event.

Keywords

Catalyst Pharmaceuticals, CPRX, Patrick J. McEnany, Insider Transaction, Form 4, Restricted Stock Units, Equity Compensation, Director Ownership, Chairman